Sublingual Sufentanil NanoTabs Are Superior to IV Morphine for Acute Post-Surgical Pain Management, AcelRx Announces

Share this content:
(ChemotherapyAdvisor) – Sublingual opioid sufentanil NanoTab PCA (patient-controlled analgesia) is superior to intravenous PCA morphine for post-surgical acute pain management, according to an open-label, randomized phase 3 non-inferiority and efficacy study announced by AcelRx Pharmaceuticals.

A primary endpoint of non-inferiority using patient global assessments (PGA) of pain was met, company officials announced. The study enrolled 359 adult patients at 26 sites across the United States, randomizing patients 1:1 to receive either sufentanil (15 µg/dose) or morphine (1 mg/dose) for the control of acute post-operative pain at 24, 48, and 72 hours after major abdominal or orthopedic surgery.

At 48 hours, 78.5% of patients reported PGA ratings of “good” or “excellent” pain control with sufentanil, versus 66.1% of patients administered IV PCA morphine (P=0.009), the company reported. Similarly statistically-superior PGA ratings were found at 24 and 72 hours, though statistical details have not yet been announced for these time-points.

A greater percentage of patients rated sufentanil as “excellent” than rated morphine as “excellent” (42.9% vs. 30.6%; P=0.016), the company noted.

Nurses and patients “rated Sufentanil NanoTab PCA System higher for overall satisfaction and ease of care compared to IV PCA morphine,” stated a company announcement. Adverse event and study drop-out rates were not statistically different for sufentanil and morphine-arm participants.

"With these impressive top-line results from this head-to-head clinical trial, we have successfully completed an important step towards our New Drug Application (NDA) submission and, dependent on completing the remaining Phase 3 trials and obtaining FDA approval, eventual commercialization of the Sufentanil NanoTab PCA System," said AcelRx President and CEO Richard King. "Delivering patient-controlled analgesia in a non-invasive, pre-programmed system that provides powerful pain control while enhancing patient ease of care and satisfaction and nurse satisfaction compared to current invasive delivery systems will be a major advance for hospital care."

Additional information about the phase 3 clinical trials with the NanoTab System is available online at using the clinical trial identifiers NCT01660763, NCT01539642 and NCT01539538.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs